



**GMMM** Interface Prescribing  
Subgroup



**Agenda**

**8<sup>th</sup> January 2015, 1pm-3pm**

**HMR CCG**

**Room G10, Number One Riverside, Smith St. Rochdale OL16 1XU**

[Declarations of Interest](#) (new declarations only)

Apologies:

	<b>ENC</b>
<b>1) Draft Minutes of 11<sup>th</sup> December 2014</b>	Item 1
<b>2) Matters Arising</b> <ul style="list-style-type: none"> <li>a) Domperidone Paediatric Use – RAG status</li> <li>b) RAG List Recommendations from Oct meeting – comments received</li> <li>c) LHRH analogue for prostate cancer SCP – further comments received</li> <li>d) Chapter 10 SCP Review &amp; Metoject® SCP</li> <li>e) Chapter 5 SCP Review – colistimethate for non-CF patients</li> <li>f) Chapter 9 SCP Review – hydroxycarbamide (sickle cell)</li> <li>g) Chapter 9 SCP Review - Cinacalcet primary hyperparathyroidism</li> <li>h) RAG List Recommendations from Nov &amp; Dec meeting (Chapter 4)</li> <li>i) Antidementia Drugs – information sheet to support RAG status</li> <li>j) Chapter 4 SCP Review – proposed list of SCPs</li> <li>k) Modafinil RAG status review – currently AMBER</li> </ul>	Item 2b Item 2c Item 2f Item 2g Item 2h Item 2i Item 2j Item 2k
<b>3) Ranolazine – review of RAG status</b>	Item 3
<b>4) Fosfomycin (oral) – RAG status required</b>	Item 4
<b>5) Ulipristal acetate (Esyma®) 5mg – RAG status required</b>	Item 5
<b>6) Removal of SCPs for colistin, Tobi®, Bramitob® and Cayston® from GMMM website</b>	
<b>7) New Drugs from NTS and Formulary Subgroup Requiring a RAG Status</b> <ul style="list-style-type: none"> <li>a) Denosumab for men – already on RAG list as Amber for other indications.</li> </ul>	
<b>8) Shared Care Protocols for Approval</b> <ul style="list-style-type: none"> <li>• Melatonin</li> </ul>	Item 8

<b>9) Expired Shared Care Protocols of GMMMG Website as of Nov 2014</b>	Item 9
<b>10) Forward work plan</b>	Item 10
<b>11) Updates from other groups</b>	
a) Formulary Subgroup (verbal)	
b) New Therapies Subgroup (verbal)	
c) GMMMG (verbal)	
<b>12) Chapter 6 RAG list review – drugs for review (if time permits)</b>	Item 12
a) Infertility Drugs – currently Red	
b) Denosumab – currently Amber	
c) GLP-1 agonists – currently Green	
d) Growth hormone (children) - currently Amber	
e) Growth hormone (adults) – currently Amber	
f) Ibandronic acid (breast cancer) – currently Amber	
g) Insulin + GLP-1 – currently Green (following specialist initiation)	
h) LHRH analogues – currently Amber for licensed indications	
i) Metformin for PCOS – currently Green	
j) Pegvisomat – currently Amber	
k) Propylthiouracil - currently Green (following specialist initiation)	
l) Gliptins – currently Green	
m) Stanozolol – currently Red	
n) Testosterone products – currently Green	
o) Tolvaptan – currently Red	
p) Cyproterone – no status	
q) Epotermin alfa (Osigraft®) – no status	
r) Disodium pamidronate – no status	
s) Zolendronic acid – no status	
t) Teriparatide – no status	
u) Parathyroid hormone – no status	
<b>13) AOB</b>	
<b>Date of Next meeting: 12th February 2015, 1pm-3pm Room 410, HMR CCG, Number One Riverside, Smith St, Rochdale OL16 1XU</b>	